Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
About this item
Full title
Author / Creator
Butrynski, James E , D'Adamo, David R , Hornick, Jason L , Dal Cin, Paola , Antonescu, Cristina R , Jhanwar, Suresh C , Ladanyi, Marc , Capelletti, Marzia , Rodig, Scott J , Ramaiya, Nikhil , Kwak, Eunice L , Clark, Jeffrey W , Wilner, Keith D , Christensen, James G , Jänne, Pasi A , Maki, Robert G , Demetri, George D and Shapiro, Geoffrey I
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
A subgroup of inflammatory myoblastic tumors (IMTs) have gene rearrangements that activate anaplastic lymphoma kinase (ALK). The authors report a case of IMT in which ALK was aberrantly expressed and the tumor had a response to crizotinib, an ALK kinase inhibitor.
Inflammatory myofibroblastic tumors (IMTs) occur primarily during the first two de...
Alternative Titles
Full title
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Authors, Artists and Contributors
Author / Creator
D'Adamo, David R
Hornick, Jason L
Dal Cin, Paola
Antonescu, Cristina R
Jhanwar, Suresh C
Ladanyi, Marc
Capelletti, Marzia
Rodig, Scott J
Ramaiya, Nikhil
Kwak, Eunice L
Clark, Jeffrey W
Wilner, Keith D
Christensen, James G
Jänne, Pasi A
Maki, Robert G
Demetri, George D
Shapiro, Geoffrey I
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3014292
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3014292
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1007056
